A new chemical bonding process can add new functions to stainless steel and make it a more useful material for implanted biomedical devices. Developed by an interdisciplinary team at the University of Alberta and Canada's National Institute for Nanotechnology, this new process was developed to address some of the problems associated with the introduction of stainless steel into the human body.
Implanted biomedical devices, such as cardiac stents, are implanted in over 2 million people every year, with the majority made from stainless steel. Stainless steel has many benefits - strength, generally stability, and the ability to maintain the required shape long after it has been implanted. But, it can also cause severe problems, including blood clotting if implanted in an artery, or an allergenic response due to release of metal ions such as nickel ions.
The University of Alberta campus is home to a highly multidisciplinary group of researchers, the CIHR Team in for Glyconanotechnology in Transplantation, that is looking to develop new synthetic nanomaterials that modify the body's immune response before an organ transplant. The ultimate goal is to allow cross-blood type organ transplants, meaning that blood types would not necessarily need to be matched between donor and recipient when an organ becomes available for transplantation. Developing new nanomaterials that engage and interact with the body's immune system are an important step in the process. In order to overcome the complex range of requirements and issues, the project team drew on expertise from three major areas: surface science chemistry and engineering, carbohydrate chemistry, and immunology and medicine.
For the transplantation goals of the project, sophisticated carbohydrate (sugar) molecules needed to be attached to the stainless steel surface to bring about the necessary interaction with the body's immune system. Its inherent stainless characteristic makes stainle
|Contact: Dr. Jillian Buriak|
National Institute for Nanotechnology